Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Metrics to compare | IMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −3.9x | −0.6x | |
PEG Ratio | −0.57 | 0.09 | 0.00 | |
Price/Book | 1.8x | 4.0x | 2.6x | |
Price / LTM Sales | - | 111.6x | 3.2x | |
Upside (Analyst Target) | 136.9% | 47.3% | 41.8% | |
Fair Value Upside | Unlock | −10.2% | 5.1% | Unlock |